- O-3.97%
- world+12.72%
BlockBeats News, August 20th, UBS Group announced that it has raised Moderna's (MRNA.O) price target from $50 to $150.
Earlier reports stated that Moderna, in collaboration with Mercedez, has achieved significant success in a Phase III clinical trial of a personalized mRNA cancer vaccine targeting high-risk melanoma. This is the world's first mRNA cancer therapy to prove effective in a large-scale Phase III trial. Following the announcement, Moderna's stock price surged by nearly 177% in a single day.
Disclaimer: Konten ini berasal dari pihak lain atau diterjemahkan oleh AI dari pihak lain. CoinEx tidak menjamin konten ini benar, asli, atau akurat, dan tidak memberikan saran investasi. Harga aset kripto sangat tidak stabil, jadi harap berhati-hati terhadap risiko yang ada.
- KriptoHargaPerubahan 24J